Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 227

Sort by

Sort Order Select

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral

Sarit Assouline, MD, Shen Li, MD, Christian Gisselbrecht, MD, Patrick Fogarty, Annette E. Hay, Eric Van Den Neste, MD, Lois E. Shepherd, Norbert Schmitz, MD, Tara Baetz, Armand Keating, MD, Sue Robinson, MD, Matthew D. Seftel, FRCP,FRCPC,MPH,MD, Caterina Stelitano, Marina S. Djurfeldt, Ralph Meyer, Bingshu E. Chen, Michael Crump, MD FRCPC

Blood (2019) 134 (Supplement_1): 768.

https://doi.org/10.1182/blood-2019-124879

Published: 2019

Journal Articles

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2019) 134 (Supplement_1): 761.

https://doi.org/10.1182/blood-2019-121521

Published: 2019

Journal Articles

Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents

R. Alejandro Sica, MD, Michael A Spinner, John S Tamaresis, PhD, Ranjana H Advani, MD, Laura J Johnston, MD, Robert Lowsky, MD, Everett H Meyer, MD PhD, David B Miklos, MD PhD, Lori S Muffly, MD, Andrew R Rezvani, MD, Judith A Shizuru, MD PhD, Wen-Kai Weng, MD PhD, Robert S. Negrin, MD, Sally Arai, MD

Blood (2019) 134 (Supplement_1): 2022.

https://doi.org/10.1182/blood-2019-131532

Published: 2019

Journal Articles

The Addition of Bortezomib to R-DHAP Does Not Improve the Response Pre-Stem Cell Transplantation Compared to Standard R-DHAP in Young Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results of the Phase II Randomized Trial FIL-VERAL12 of the Fondazione Italiana Linfomi

Blood (2019) 134 (Supplement_1): 2025.

https://doi.org/10.1182/blood-2019-130786

Published: 2019

Journal Articles

Triangle: Autologous T ransplantation after a R ituximab/ I brutinib/ a ra-c Containing I n duction in G eneralized Mantle Cell L ymphoma - a Randomized E uropean MCL Network Trial

Martin Dreyling, MD, Marco Ladetto, MD, Jeanette K. Doorduijn, MD PhD, Eva Gine, MD, Mats Jerkeman, MD Professor, Ulrich Mey, MD, Michal Szymczyk, MD, Martin Hutchings, MD PhD, Arne Kolstad, MD PhD, Gregor Verhoef, MD PhD, Marek Trneny, MD prof, Maria Gomes da Silva, MD, Christiane Pott, MD PhD, Wolfram Klapper, Michael Unterhalt, PhD, Eva Hoster, PhD

Blood (2019) 134 (Supplement_1): 2816.

https://doi.org/10.1182/blood-2019-127863

Published: 2019

Journal Articles

Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study

Pallawi Torka, MD, Nishitha Reddy, MD, Adrienne Groman, MS, Angela Kader, Jenna Nichols, Alan Hutson, Cory Mavis, MSc, Joseph Dennis Tario, PhD, Paul K. Wallace, MS, PhD, AnneMarie W. Block, PhD, Sheila N. J. Sait, PhD, Bora E Baysal, MD PhD, Vishala T. Neppalli, MD, Suchitra Sundaram, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 2817.

https://doi.org/10.1182/blood-2019-123488

Published: 2019

Journal Articles

Long-Term Clinical and Molecular Remissions in Patients with Mantle Cell Lymphoma (MCL) Following High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Bernd Metzner, MD PhD, Jochen Casper, MD PhD, Koehne Claus-Henning, MD PhD, Andrea Renzelmann, MD, Thomas H. Mueller, MD PhD, Eduard K. Petershofen, MD PhD, Bernd Rosien, MD, Ruth Thole, MD, Andreas Voss, MD, Martin H. Dreyling, MD PhD, Eva Hoster, PhD, Wolfram Klapper, Christiane Pott, MD PhD

Blood (2019) 134 (Supplement_1): 2819.

https://doi.org/10.1182/blood-2019-122353

Published: 2019

Journal Articles

Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre

John Radford, Ellie White, Felipe A. Castro, PhD, Anshuman Chaturvedi, FRCPath, Nathalie Spielewoy, PhD, Adam Gibb, MBBS, Andy Surinach, MPH, Kim Linton, PhD, Aijing Shang, MD PhD, Michael Wenger, MD

Blood (2019) 134 (Supplement_1): 2917.

https://doi.org/10.1182/blood-2019-123664

Published: 2019

Journal Articles

Ex-Vivo Drug Response Profiling for Tailoring Treatment in Hematologic Malignancies: The Prospective Non-Interventional SMART-Trial

Nora Liebers, Peter-Martin Bruch, Agnes Gambietz, Holly Giles, BA, Junyan Lu, PhD, Mareike Knoll, Carolin Kolb, Peter Dreger, Carsten Mueller-Tidow, MD, Wolfgang Huber, PhD, Axel Benner, Thorsten Zenz, MD, Sascha Dietrich, MD

Blood (2019) 134 (Supplement_1): 376.

https://doi.org/10.1182/blood-2019-125324

Published: 2019

Journal Articles

Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden

Karin Ekstrom Ekstroem Smedby, Sara Ekberg, Sandra Eloranta, Gunilla Enblad, Mats Jerkeman, MD Professor, Per-Ola Andersson, MD PhD, Sara Harrysson, MD

Blood (2019) 134 (Supplement_1): 4111.

https://doi.org/10.1182/blood-2019-123785

Published: 2019

Journal Articles

Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients in China in the Rituximab Era

Yun Li, MD PhD, Meng Wu, MD, Huiqiang Huang, MD PhD, Wei Xu, MD PhD, Haiwen Huang, MD PhD, Weili Zhao, MD PhD, Yanyan Wang, MD, Shuo Liu, MD, Pengpeng Xu, MD, Zhengming Chen, Yuqin Song, MD PhD, Jia Ruan, MD PhD, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 3994.

https://doi.org/10.1182/blood-2019-125192

Published: 2019

Journal Articles

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

Xudong Zhang, Junxia Hu, Qingjiang Chen, Mingzhi Zhang, MD PhD, Ken H. Young

Blood (2019) 134 (Supplement_1): 5221.

https://doi.org/10.1182/blood-2019-128424

Published: 2019

Journal Articles

PD-1 Inhibitor Combined with Chemotherapy As a Salvage Therapy for Refractory DLBCL

Xin Li, Rui Zhang, Qing Li, Juan Mu, Yedi Pu, Yili Jiang, Qi Deng

Blood (2019) 134 (Supplement_1): 5357.

https://doi.org/10.1182/blood-2019-128035

Published: 2019

Journal Articles

Romidepsin-CHOEP Plus Intensification with up-Front Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: Final Results of Phase Ib PTCL13 Study of the Fondazione Italiana Linfomi

Annalisa Chiappella, MD, Cristiana Carniti, Andrea Evangelista, PhD, Maria Giuseppina Cabras, MD, Alessandro Re, MD, Manuela Zanni, MD, Vittorio Stefoni, Armando Santoro, MD, Angela Giovanna Congiu, Anna Dodero, MD, Stefano A. Pileri, MD PhD, Giovannino Ciccone, MD, Paolo Corradini, MD

Blood (2018) 132 (Supplement 1): 2902.

https://doi.org/10.1182/blood-2018-99-119763

Published: 2018

Journal Articles

Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study

Anton Hagenbeek, MD PhD, Josée M Zijlstra, MD, Wouter J Plattel, MD, Franck Morschhauser, MD, Petronella J Lugtenburg, MD PhD, Pauline Brice, MD, Martin Hutchings, MD, Thomas Gastinne, MD, Roberto D Liu, Coreline N Burggraaf, MD, Marcel Nijland, MD, Sanne H Tonino, MD PhD, Harm van Tinteren, MSc, Marta I Lopez Yurda, MSc, Marie José Kersten, MD PhD

Blood (2018) 132 (Supplement 1): 2923.

https://doi.org/10.1182/blood-2018-99-112235

Published: 2018

Journal Articles

Induction Therapy with Everolimus in Combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Randomized, Placebo-Controlled Phase I/II Trial (HD-R3i)

Bastian von Tresckow, MD, Andreas Hüttmann, MD, Vladan Vucinic, MD, Horst Mueller, PhD, Annette Plütschow, Andreas Viardot, MD, Max S. Topp, Carsten Kobe, MD, Boris Böll, MD, Dennis A. Eichenauer, Stephanie Sasse, MD, Heinz Haverkamp, Michael Fuchs, Andreas Engert, MD, Peter Borchmann, MD

Blood (2018) 132 (Supplement 1): 2912.

https://doi.org/10.1182/blood-2018-99-117291

Published: 2018

Journal Articles

The iR 2 Regimen(Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 402.

https://doi.org/10.1182/blood-2018-99-111163

Published: 2018

Journal Articles

Clonal Evolution of a Mutation in PTPRA As a Potential Cause for Resistance Against Anti-CD19 Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy with CTL019 in DLBCL Patients

Hyatt Balke-Want, MD, Philipp Gödel, MD, Nima Abedpour, PhD, Martin Peifer, PhD, Peter Borchmann, MD

Blood (2018) 132 (Supplement 1): 4119.

https://doi.org/10.1182/blood-2018-99-110600

Published: 2018

Journal Articles

Gemcitabine, Dexamethasone, Cisplatin +/- Rituximab (GDP +/- R) Is Highly Effective As a Mobilization Regimen in Relapsed or Refractory Lymphoma (COLLYM STUDY)

Jean-Philippe Adam, BPharm, MSc, Vincent T. Taillefer, Pharm.D, Marianne Emond, B.Pharm, M.Sc, BCOP, Marie-Hélène Leblanc, B.Pharm, M.Sc, BCOP, Olivier Besner-Morin, B.Pharm, M.Sc, Stephane Doucet, MD FRCPC

Blood (2018) 132 (Supplement 1): 3348.

https://doi.org/10.1182/blood-2018-99-115539

Published: 2018

NARROW

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents

The Addition of Bortezomib to R-DHAP Does Not Improve the Response Pre-Stem Cell Transplantation Compared to Standard R-DHAP in Young Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results of the Phase II Randomized Trial FIL-VERAL12 of the Fondazione Italiana Linfomi

Triangle: Autologous T ransplantation after a R ituximab/ I brutinib/ a ra-c Containing I n duction in G eneralized Mantle Cell L ymphoma - a Randomized E uropean MCL Network Trial

Ofatumumab Plus Hypercvad/MA Induction Leads to High Rates of Minimal Residual Disease (MRD) Negativity in Patients with Newly Diagnosed Mantle Cell Lymphoma, Results of a Phase 2 Study

Long-Term Clinical and Molecular Remissions in Patients with Mantle Cell Lymphoma (MCL) Following High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre

Ex-Vivo Drug Response Profiling for Tailoring Treatment in Hematologic Malignancies: The Prospective Non-Interventional SMART-Trial

Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden

Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients in China in the Rituximab Era

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

PD-1 Inhibitor Combined with Chemotherapy As a Salvage Therapy for Refractory DLBCL

Romidepsin-CHOEP Plus Intensification with up-Front Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: Final Results of Phase Ib PTCL13 Study of the Fondazione Italiana Linfomi

Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study

Induction Therapy with Everolimus in Combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Randomized, Placebo-Controlled Phase I/II Trial (HD-R3i)

The iR 2 Regimen(Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma

Clonal Evolution of a Mutation in PTPRA As a Potential Cause for Resistance Against Anti-CD19 Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy with CTL019 in DLBCL Patients

Gemcitabine, Dexamethasone, Cisplatin +/- Rituximab (GDP +/- R) Is Highly Effective As a Mobilization Regimen in Relapsed or Refractory Lymphoma (COLLYM STUDY)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only